The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback